idc btig estim compani document
million except per share amount
mix quarter target revis concern
share finish today follow
co report mix result weaker forecast top line
revenu vs estimate exceed ep forecast ep
vs estimate benefit lower expect sg expens see
page note detail believ share appear under-valued
trade ev ebitda think outstand financi question
propos transact merg rate legaci upjohn segment
remain think deal combin upjohn merit
concern impact china drug procur program upjohn
lipitor norvasc brand sale seem recurr concern investor
morn myl chairman robert couri reiter comfort propos
transact target close
increas ep forecast
result benefit growth three key geographi
america yoy europ yoy row co
gener adj financi target revenu revis
 top end guidanc lower
co cite gener product launch delay restasi well foreign
currenc headwind upcom us product launch includ ogiviri
biosimilar version herceptin trastuzumab monoclon antibodi
posit metastat cancer could one first enter multi-
billion brand market howev multipl co approv
make launch competit remain track get
new product launch year new product
remain focus target pay debt year
end co debt estim debt ebitda ratio
valuat rate share buy pt base multipl
free estim discount back
rate share buy pt near-term fundament remain challeng result price
eros across key gener rx segment think co benefit global footprint addit
believ launch biosimilar includ fulphila lead signific new product revenu next
announc plan merg new co
upjohn legaci segment expect manag co provid
addit detail financi profil new co earli juli
co host call provid top line revenu guidanc upjohn
 expect adj ebitda margin
estim gener revenu adj ep
driven launch new product includ fulphila wixela inhub
stronger expect volum sale gain new product launch
better expect launch ogiviri biosimilar herceptin
global specialti
pharmaceut co lead
market share posit us
gener space intern
oper across europ asia
weaker expect sale profit gener result lower
share finish today follow co report mix result weaker forecast
top line revenu vs estimate exceed ep forecast ep vs estimate
benefit lower expect sg expens result benefit growth three
key geographi america yoy europ yoy row co gener adj
financi target revenu revis top end guidanc lower
co cite gener product launch delay restasi well foreign currenc headwind upcom
us product launch includ ogiviri biosimilar version herceptin trastuzumab monoclon antibodi
metastat cancer could one first enter multi-billion brand market howev multipl co
approv make launch competit anoth major product opportun could gener
lantu expect fda make approv decis potenti remain track
get new product launch year new product sale gener ytd
guidancebtig revenu adj free co report btig estimatesfinanci guidanc btig estimatesmylan higherincom statement cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut analysissal co report btig estim
wixela inhub launch progress gsk put fenc protect market share advair late januari
fda approv myl gener version advair fluticasone/salmeterol treatment asthma/copd estim
brand market opportun us base analysi symphoni health volum data wixela inhub
market share estim gener advair sale
myl gener version advair wixela inhub includ three strength mcg mcg
mcg asthma patient sold discount brand counterpart advair disku less gsk
author gener version accord symphoni health product garner share total volum sinc
launch februari
 breo advair hold share brand copdwixela inhubadvair diskusbreo wixela inhub market sharewixela inhubadvair disku
base sensit analysi new co financi target think share remain under-valued
recogn investor wonder whether pro-forma guidanc optimist base new
co gener revenu adjust ebitda modest level cost synergi
think share worth per share base multipl ebitda per share multipl
ebitda per share valuat multipl
implli ev new co valuat base ebitda estim multipl base equiti valuat base ownership new co impli debt includ capit equiti share per share base equiti valuat base ownership new co impli debt includ capit equiti share per share base equiti valuat base ownership new co impli debt includ capit equiti share per share
 incom statement financi project cost sg adj oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut co report btig
btig cover compani mention report
appendix analyst certif import disclosur
